1615208-41-7
Chemical Structure
CHF-6366
- CAS. Nr.: 1615208-41-7
- Formula:C42H48N6O8
- Molecular Weight:764.87
IUPAC Name: 4-(((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)butyl 1-methyl-5-((3-((S)-phenyl(((((R)-quinuclidin-3-yl)oxy)carbonyl)amino)methyl)phenoxy)methyl)-1H-pyrazole-3-carboxylate
InChIKey: YWSIONULMMKTSJ-UZGNFBRWSA-N
SMILES: O=C(C1=NN(C)C(COC2=CC=CC([C@H](C3=CC=CC=C3)NC(O[C@H]4CN5CCC4CC5)=O)=C2)=C1)OCCCCNC[C@H](O)C6=CC=C(O)C7=C6C=CC(N7)=O
Biological Activity: CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD)[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CHF-6366 | CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
